The global digital health market is poised for robust growth over the next decade, with its value projected to rise from USD 347.4 billion in 2025 to USD 1,830.4 billion by 2033, reflecting a compound annual growth rate (CAGR) of 23.4% between 2026 and 2033, according to a recent report by Grand View Research.

The rapid evolution of healthcare delivery, widespread adoption of digital technologies in clinical settings, increasing demand for remote healthcare solutions, and the growing emphasis on patient-centered care are driving the expansion of the global digital health market. Governments, healthcare providers, and technology companies worldwide are investing heavily in digital infrastructure to enhance healthcare accessibility, efficiency, and patient outcomes.

Digital Technologies Transforming Healthcare Systems
Digital health solutions have become an essential component of modern healthcare by enabling connected care, virtual consultations, electronic health records, real-time patient monitoring, and data-driven clinical decision-making. Factors such as the rising burden of chronic diseases, shortages of healthcare professionals, increasing healthcare expenditures, and growing consumer preference for convenient healthcare services continue to support market growth.

The widespread use of smartphones, improved internet access, advances in healthcare IT systems, and rising investments in health technologies are accelerating the global adoption of digital health platforms. Solutions such as remote patient monitoring, telehealth services, and mobile health applications are increasingly being utilized to provide continuous access to healthcare services.

Telehealth and Mobile Health Continue to Drive Expansion
Among technology segments, telehealth accounted for the largest share of the digital health market in 2025, representing 44.7% of total revenue. This growth has been fueled by rising demand for virtual healthcare services, expanding internet connectivity, increasing smartphone usage, and greater acceptance of remote consultations.

Advancements in telehealth platforms have enabled healthcare professionals to provide consultations, patient monitoring, and follow-up care outside traditional clinical environments. Growing healthcare costs and the need to improve access in underserved regions are further accelerating the adoption of virtual care models.

At the same time, the mobile health (mHealth) segment is experiencing rapid growth as consumers increasingly rely on smartphones and wearable devices to monitor health conditions, manage chronic illnesses, and access personalized healthcare services. Continued improvements in mobile technologies and digital awareness are expected to further support this segment's expansion.

Software Solutions Account for the Largest Market Share
Based on component type, software represented the largest share of the digital health market in 2025, accounting for 45.7% of revenue. The segment's growth is being driven by the increasing adoption of healthcare software platforms by patients, providers, insurers, and medical institutions.

Healthcare organizations are deploying a broad range of digital solutions, including electronic health record (EHR) systems, healthcare analytics platforms, digital therapeutics, and clinical management software to enhance operational performance and improve patient care.

The integration of artificial intelligence (AI), machine learning, and advanced analytics technologies is also reshaping healthcare by supporting predictive analytics, more accurate diagnoses, and personalized treatment strategies.

Growing Chronic Disease Burden Supports Market Demand
The increasing prevalence of chronic conditions such as diabetes, cardiovascular disease, and cancer is creating substantial demand for digital healthcare technologies that enable continuous monitoring and disease management.

The diabetes application segment accounted for more than 25% of the market in 2025, driven by increasing adoption of glucose monitoring systems, digital disease management platforms, wearable technologies, and remote patient monitoring solutions.

Digital health platforms are empowering patients by improving access to healthcare information, supporting medication adherence, and enabling healthcare providers to remotely monitor patient health and treatment outcomes.

Patient-Centered Care Models Create New Opportunities
Patients represented the largest end-user segment in 2025, accounting for more than 35% of total market revenue, and are expected to maintain strong growth throughout the forecast period. The rising focus on personalized care, self-management tools, and improved patient engagement continues to drive adoption.

Digital healthcare solutions, including mobile applications, wearable devices, telehealth platforms, and connected medical technologies, are enabling patients to take a more active role in preventive care and disease management.

Healthcare providers are likewise adopting digital tools to improve clinical workflows, increase operational efficiency, and deliver more personalized treatment approaches.

North America Leads While Asia Pacific Emerges as a High-Growth Region
North America held the largest share of the global digital health market in 2025, accounting for 37.1% of total revenue. The region's leadership is supported by advanced healthcare infrastructure, significant healthcare IT investments, supportive government policies, and rapid adoption of emerging technologies.

The region continues to attract substantial investment from healthcare organizations, technology companies, and startups focused on developing innovative digital health solutions.
Meanwhile, the Asia Pacific market is expected to experience strong growth during the forecast period, driven by increasing smartphone penetration, improving healthcare infrastructure, expanding digital literacy, and government initiatives aimed at accelerating healthcare digitalization.

Investments and Innovation Intensify Industry Competition
The digital health sector is witnessing growing levels of investment, strategic partnerships, and technological innovation as companies seek to strengthen and expand their digital healthcare capabilities. Industry participants are actively developing solutions across telehealth, healthcare analytics, wearable devices, remote monitoring, and connected healthcare ecosystems.

Major companies operating in the market include Oracle Cerner, Veradigm, Apple Inc., Telefonica S.A., McKesson Corporation, Epic Systems Corporation, Google, Samsung Electronics, IBM Corporation, and Cisco Systems.

Recent developments across the industry underscore a growing focus on artificial intelligence integration, digital care delivery models, and technology-enabled healthcare services. These innovations are expected to unlock new opportunities for market participants while improving healthcare access on a global scale.

Digital Health Market Outlook
The global digital health industry is entering a period of accelerated transformation as healthcare systems increasingly embrace technology-driven solutions to improve patient outcomes and operational performance. The convergence of advanced connectivity, AI-powered healthcare applications, rising healthcare investments, and growing demand for remote care services is expected to drive sustained market expansion through 2033.

According to Grand View Research, the digital health market is on track to reach USD 1,830.4 billion by 2033, highlighting the continued shift toward more connected, accessible, and personalized healthcare ecosystems worldwide.

EndoDNA, a company specializing in precision health intelligence, has introduced BIOS, an innovative and patented clinical decision-support platform designed exclusively for licensed healthcare professionals. Replacing the company's previous interpretation engine, myDNALive, BIOS provides practitioners in functional, integrative, regenerative, hormone optimization, and longevity medicine with a dynamic, long-term view of a patient's biological profile.

BIOS—short for Biomedical Reasoning and Adaptive Inference Network—takes precision medicine beyond traditional static genetic reports. Instead of offering one-time insights, the platform continuously integrates genomic information, biomarkers, lifestyle factors, symptoms, and other patient data into a unified, evolving clinical dashboard.

According to Len May, Founder and CEO of EndoDNA, healthcare providers have access to unprecedented amounts of biological data but often lack practical tools to translate that information into actionable care strategies. BIOS was developed to bridge this gap by converting complex biological information into structured clinical insights that adapt as patient conditions change, enabling more informed and consistent treatment decisions.

A Pathway-Centered Approach to Genomic Analysis
Unlike many consumer DNA services and generic artificial intelligence platforms that focus on interpreting individual single-nucleotide polymorphisms (SNPs), BIOS evaluates interconnected biological pathways. This systems-based approach allows practitioners to better understand how genetic factors influence overall health.

The platform analyzes key physiological areas, including:

Overall, BIOS evaluates approximately one million validated genetic variants across 21 biological systems and actively manages 214 curated pathways to support real-time clinical decision-making.

Four Integrated Intelligence Networks
Rather than evaluating isolated data points, BIOS uses four interconnected memory networks that collectively create a comprehensive and continuously updated patient profile:

World Network – Incorporates large-scale genomic research and evidence from established resources such as biobanks, CPIC, and PharmGKB.

Experience Network – Leverages aggregated clinical case data to identify interventions that have produced favorable outcomes in similar patient populations.

Opinion Network – Captures practitioner observations, notes, and custom adjustments to personalize recommendations.

Observation Network – Monitors patient-reported outcomes alongside biomarker and laboratory trends over time.
Through a HIPAA-compliant interface, licensed healthcare providers can order DNA testing, generate multiple specialized reports from existing genotype data, integrate laboratory and biomarker information, evaluate pharmacogenomic interactions, and perform natural-language searches of genomic datasets.

Available reporting modules include:

Dr. Allen Lawrence, MA, MD, PhD, noted that while clinicians have long struggled with the challenge of interpreting vast quantities of biological data, BIOS provides a practical framework for transforming that information into meaningful clinical action. By converting genomic and biological inputs into organized, actionable intelligence, the platform supports a more scalable model of precision medicine that enhances decision-making, patient engagement, and individualized care delivery.

Proven Accuracy and Ongoing Innovation
Since its inception, EndoDNA has supported more than 10,000 patients across over nine countries through partnerships with CAP- and CLIA-accredited laboratories. Utilizing Illumina next-generation sequencing technology, the company reports a genotyping accuracy rate of 99.6%.

EndoDNA's intellectual property portfolio includes more than ten issued and pending patents. Among these are a patented methodology for genotyping the endocannabinoid system (ECS) and a proprietary machine-learning framework designed to predict treatment effectiveness using genetic and biometric information.

BIOS is available immediately to licensed healthcare professionals as both a clinical decision-support solution and a research-focused platform.

Nucleus Genomics is actualizing the vision initially sparked by the Human Genome Project, which is to utilize genomics to enable individuals to lead healthier and longer lives.

The health application developed by Nucleus leverages the capabilities of whole-genome sequencing (WGS). WGS is an all-encompassing technique for examining entire genomes, with the ability to detect DNA variants that have both subtle and significant impacts. Unlike most other DNA analyses, WGS can reveal risks for prevalent conditions such as cardiovascular disease and cancer, and can also detect numerous rare genetic disorders.

Currently, Nucleus is collaborating with Illumina to expand their ambition of using WGS to create a more proactive healthcare system where individuals have more control. This initiative comes in the wake of a drastic reduction in the cost of sequencing a genome and aims to make WGS more accessible to the public.

The mission was born out of a tragic event. In 2005, Kian Sadeghi, the founder and CEO of Nucleus, lost his 16-year-old cousin who passed away unexpectedly in her sleep. Medical professionals speculated that she might have had long QT syndrome, a rare inherited heart condition. Sadeghi’s parents attributed it to “bad genetics.”

Sadeghi realized that a health platform that integrates genomics and lifestyle data to assess disease risks could have significantly impacted his family’s life. “That’s what we aspire to construct for everyone. That’s the potential of Nucleus,” says Sadeghi.

Sadeghi concentrated on developing a web application that would transform people’s understanding of how their DNA influences their health and well-being. After conducting thorough research, he envisioned a consumer application that incorporated the latest advancements in genomic technology and analysis, particularly WGS.

He brought together a core team of scientists, clinical geneticists, engineers, operators, and writers with diverse skills and expertise. According to Sadeghi, the strength of Nucleus lies in the team’s shared enthusiasm for introducing a unique and revolutionary product to people’s daily healthcare experience.

In 2022, Nucleus secured a total of $18 million in funding, primarily from Seven Seven Six, a venture capital firm founded by Reddit’s Alexis Ohanian, and Founders Fund, led by Peter Thiel.

“Our product will ultimately combine more than 70,000  separate genetic tests into one,” says Sadeghi. “We won’t need to have tens of thousands of different laboratories each offering a different genetic test. WGS supersedes nearly all the others, from single-gene tests for hereditary cancers to small panels and carrier screenings for rare diseases.”

Nucleus offers polygenic risk scores (PRS), an analytical method that demonstrates the cumulative effect of common DNA variants on an individual’s risk of disease and trait predispositions. The PRS analyses conducted by Nucleus can encapsulate the collective influence of over a million of these prevalent variants on each person’s health and wellness.

Their analysis takes it a step further by integrating genetic data with non-genetic information to provide a more holistic view of a user’s risk. Understanding factors such as age, body mass index, cholesterol levels, and sex assigned at birth allows Nucleus to provide both relative genetic risk percentiles and individual estimates of absolute risk. Each report presents the figures through clear visuals and comprehensible language.

“We recognize the significance of making genetic information accessible to consumers, and the equal obligation to maintain the strict confidentiality of such crucial information and ensure it remains under their complete control,” states Varun Jana, Nucleus’s Chief Technology Officer. “Nucleus will enforce some of the most rigorous data privacy and security measures in the healthcare industry.”

The company aims to increase the diversification of genomics datasets. They strive to improve the relationship between the scientific community and communities that have historically been underserved and underrepresented in medical and genetic research.

“Our team originates from four continents,” declares Sadeghi. “That diversity reflects what we aim to establish in genetic databases. One of our top priorities at Nucleus is to create a more equitable future in genomics.”

While it may be a long-term objective, the Nucleus platform currently compensates for such disparities in genetic data. “We statistically adjust for people of different ancestries, enabling anyone to obtain valuable and useful insights into their genetic predisposition. It’s a challenging problem to address, but we’re making steady progress towards the goal every day.”

Nucleus has obtained CLIA certification and is seeking CAP accreditation for its WGS informatics laboratory. The platform is set to launch in the US in 2024.

“Our objective is to significantly promote the integration of genetics into the healthcare ecosystem,” Sadeghi articulates, “and to pave the way for a new epoch of preventive healthcare.”